# Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

> **NCT01815736** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 1443 (actual)

## Conditions studied

- HIV
- HIV Infections

## Interventions

- **DRUG:** E/C/F/TAF
- **DRUG:** E/C/F/TDF
- **DRUG:** EFV/FTC/TDF
- **DRUG:** RTV
- **DRUG:** ATV
- **DRUG:** FTC/TDF
- **DRUG:** COBI

## Key facts

- **NCT ID:** NCT01815736
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-27
- **Primary completion:** 2015-03-16
- **Final completion:** 2020-04-01
- **Target enrollment:** 1443 (ACTUAL)
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01815736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01815736, "Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01815736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*